Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

A semiparametric approach to estimate rapid lung function decline in cystic fibrosis.

Szczesniak RD, McPhail GL, Duan LL, Macaluso M, Amin RS, Clancy JP.

Ann Epidemiol. 2013 Dec;23(12):771-7. doi: 10.1016/j.annepidem.2013.08.009. Epub 2013 Oct 5.

PMID:
24103586
2.

Decline in lung function does not predict future decline in lung function in cystic fibrosis patients.

Rosenfeld M, VanDevanter DR, Ren CL, Elkin EP, Pasta DJ, Konstan MW, Morgan WJ; Investigators of Coordinators of the Epidemiologic Study of Cystic Fibrosis..

Pediatr Pulmonol. 2015 Sep;50(9):856-62. doi: 10.1002/ppul.23227. Epub 2015 Jun 18.

PMID:
26086901
3.

Understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study.

Taylor-Robinson D, Whitehead M, Diderichsen F, Olesen HV, Pressler T, Smyth RL, Diggle P.

Thorax. 2012 Oct;67(10):860-6. doi: 10.1136/thoraxjnl-2011-200953. Epub 2012 May 3.

4.

Disease-specific reference equations for lung function in patients with cystic fibrosis.

Kulich M, Rosenfeld M, Campbell J, Kronmal R, Gibson RL, Goss CH, Ramsey B.

Am J Respir Crit Care Med. 2005 Oct 1;172(7):885-91. Epub 2005 Jun 23.

PMID:
15976373
5.

Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis.

Sanders DB, Bittner RC, Rosenfeld M, Redding GJ, Goss CH.

Pediatr Pulmonol. 2011 Apr;46(4):393-400. doi: 10.1002/ppul.21374. Epub 2010 Oct 21.

PMID:
20967845
6.

Variation in lung function is associated with worse clinical outcomes in cystic fibrosis.

Heinzmann-Filho JP, Pinto LA, Marostica PJ, Donadio MV.

J Bras Pneumol. 2015 Nov-Dec;41(6):509-15. doi: 10.1590/S1806-37562015000000006. English, Portuguese.

7.

Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.

Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, Olesen H; ECFS Patient Registry Steering Group..

Eur Respir J. 2014 Jan;43(1):125-33. doi: 10.1183/09031936.00166412. Epub 2013 Apr 18.

8.

Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function.

Morgan WJ, Wagener JS, Yegin A, Pasta DJ, Millar SJ, Konstan MW; Scientific Advisory Group, investigators.; coordinators of the Epidemiologic Study of Cystic Fibrosis..

J Pediatr. 2013 Oct;163(4):1152-7.e2. doi: 10.1016/j.jpeds.2013.05.013. Epub 2013 Jun 27.

9.

Nutritional growth retardation is associated with defective lung growth in cystic fibrosis: a preventable determinant of progressive pulmonary dysfunction.

Thomson MA, Quirk P, Swanson CE, Thomas BJ, Holt TL, Francis PJ, Shepherd RW.

Nutrition. 1995 Jul-Aug;11(4):350-4.

PMID:
8580575
11.

Predictors of deterioration of lung function in cystic fibrosis.

Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfält R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L.

Pediatr Pulmonol. 2002 Jun;33(6):483-91.

PMID:
12001283
12.

Long-term gas exchange characteristics as markers of deterioration in patients with cystic fibrosis.

Kraemer R, Latzin P, Pramana I, Ballinari P, Gallati S, Frey U.

Respir Res. 2009 Nov 12;10:106. doi: 10.1186/1465-9921-10-106.

13.

A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis.

Harun SN, Wainwright C, Klein K, Hennig S.

Paediatr Respir Rev. 2016 Sep;20:55-66. doi: 10.1016/j.prrv.2016.03.002. Epub 2016 Mar 14. Review.

PMID:
27259460
14.

Pulmonary function in individuals who underwent liver transplantation: from the US cystic fibrosis foundation registry.

Miller MR, Sokol RJ, Narkewicz MR, Sontag MK.

Liver Transpl. 2012 May;18(5):585-93. doi: 10.1002/lt.23389.

15.

Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis.

Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP.

Am J Respir Crit Care Med. 2008 Oct 15;178(8):814-21. doi: 10.1164/rccm.200802-327OC. Epub 2008 Jul 31.

PMID:
18669817
16.

Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis.

Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, De Rose V.

Respir Med. 2009 Mar;103(3):407-13. doi: 10.1016/j.rmed.2008.09.024. Epub 2008 Nov 22.

17.

The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis.

Sawicki GS, Rasouliyan L, Pasta DJ, Regelmann WE, Wagener JS, Waltz DA, Ren CL; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis..

Pediatr Pulmonol. 2008 Nov;43(11):1117-23. doi: 10.1002/ppul.20914.

PMID:
18846559
18.

Progressive flow-to-volume dysanapsis in cystic fibrosis: a predictor for lung transplantation?

Vilozni D, Lavie M, Sarouk I, Efrati O.

Am J Respir Crit Care Med. 2012 Jul 1;186(1):82-7. doi: 10.1164/rccm.201202-0272OC. Epub 2012 Apr 26.

PMID:
22538801
19.

Lung function decline from adolescence to young adulthood in cystic fibrosis.

Vandenbranden SL, McMullen A, Schechter MS, Pasta DJ, Michaelis RL, Konstan MW, Wagener JS, Morgan WJ, McColley SA; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis..

Pediatr Pulmonol. 2012 Feb;47(2):135-43. doi: 10.1002/ppul.21526. Epub 2011 Aug 24.

20.

Improving rate of decline of FEV1 in young adults with cystic fibrosis.

Que C, Cullinan P, Geddes D.

Thorax. 2006 Feb;61(2):155-7. Epub 2005 Dec 29.

Supplemental Content

Support Center